ATE534623T1 - 2-alkyliden-18,19-dinor-vitamin-d-verbindungen - Google Patents
2-alkyliden-18,19-dinor-vitamin-d-verbindungenInfo
- Publication number
- ATE534623T1 ATE534623T1 AT05722702T AT05722702T ATE534623T1 AT E534623 T1 ATE534623 T1 AT E534623T1 AT 05722702 T AT05722702 T AT 05722702T AT 05722702 T AT05722702 T AT 05722702T AT E534623 T1 ATE534623 T1 AT E534623T1
- Authority
- AT
- Austria
- Prior art keywords
- compounds
- activity
- alkylidene
- diseases
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 229940088594 vitamin Drugs 0.000 title 1
- 229930003231 vitamin Natural products 0.000 title 1
- 235000013343 vitamin Nutrition 0.000 title 1
- 239000011782 vitamin Substances 0.000 title 1
- 210000000988 bone and bone Anatomy 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011540 hip replacement Methods 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 238000013150 knee replacement Methods 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 230000011164 ossification Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000027425 release of sequestered calcium ion into cytosol Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/821,828 US7713951B2 (en) | 2004-04-09 | 2004-04-09 | 2-alkylidene-18,19-dinor-vitamin D compounds |
| PCT/US2005/003378 WO2005102995A1 (en) | 2004-04-09 | 2005-02-04 | 2-alkylidene-18,19-dinor-vitamin d compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE534623T1 true ATE534623T1 (de) | 2011-12-15 |
Family
ID=34960524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05722702T ATE534623T1 (de) | 2004-04-09 | 2005-02-04 | 2-alkyliden-18,19-dinor-vitamin-d-verbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7713951B2 (enExample) |
| EP (1) | EP1735277B1 (enExample) |
| JP (1) | JP4988551B2 (enExample) |
| AT (1) | ATE534623T1 (enExample) |
| AU (1) | AU2005235957B2 (enExample) |
| CA (1) | CA2562535C (enExample) |
| MX (1) | MXPA06011499A (enExample) |
| NZ (1) | NZ550234A (enExample) |
| WO (1) | WO2005102995A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7834050B2 (en) | 2006-03-29 | 2010-11-16 | Duke University | Small molecule insulin mimetics absent quinones |
| JP2009532457A (ja) * | 2006-04-06 | 2009-09-10 | ウイスコンシン アラムニ リサーチ ファンデーション | ２−メチレン−１α−ヒドロキシ−１８，１９，２１−トリノルビタミンＤ３類縁体およびその使用 |
| US7704981B2 (en) * | 2006-04-06 | 2010-04-27 | Wisconsin Alumni Research Foundation | 2-methylene-1alpha,25-dihydroxy-18,19,21-trinorvitamin D3 and uses thereof |
| US20110274743A1 (en) * | 2009-01-16 | 2011-11-10 | Pharmaceutical Compounding Nz Limited | Medicament for the Treatment of Pain and Inflammation |
| CA2777938C (en) * | 2009-10-21 | 2017-11-14 | Wisconsin Alumni Research Foundation | Method of preventing type 1 diabetes |
| US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
| JP5931845B2 (ja) * | 2010-03-23 | 2016-06-08 | ウイスコンシン アラムニ リサーチ ファンデーション | ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー |
| CA2794006C (en) * | 2010-03-23 | 2017-11-28 | Wisconsin Alumni Research Foundation | (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3 |
| JP5930467B2 (ja) * | 2012-12-14 | 2016-06-08 | 花王株式会社 | ニトリル化合物 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL67153A (en) | 1981-11-02 | 1986-12-31 | Res Inst Medicine Chem | Intermediates in the production of vitamin d analogues and method for their production |
| US4666634A (en) | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| GB8904154D0 (en) | 1989-02-23 | 1989-04-05 | Leo Pharm Prod Ltd | Chemical compounds |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| NZ232734A (en) | 1989-03-09 | 1991-11-26 | Wisconsin Alumni Res Found | 19-nor vitamin d derivatives and pharmaceutical compositions |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| AU649057B2 (en) | 1990-08-24 | 1994-05-12 | Wisconsin Alumni Research Foundation | Methods and compositions containing vitamin D compounds for improvement of skin conditions |
| EP0474517B1 (en) | 1990-09-07 | 1998-11-18 | Wisconsin Alumni Research Foundation | Novel use of 1alpha-hydroxylated-19-nor-vitamin D compounds to treat psoriasis |
| US5086191A (en) | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| AU650751B2 (en) | 1991-05-28 | 1994-06-30 | Wisconsin Alumni Research Foundation | Novel synthesis of 19-nor vitamin D compounds |
| DE69400495T2 (de) | 1993-04-05 | 1997-04-30 | Wisconsin Alumni Res Found | 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle |
| JP4235256B2 (ja) * | 1993-07-09 | 2009-03-11 | カー・イュー・ルーベン・リサーチ・アンド・ディベロップメント | 新規ビタミンｄ構造類似体 |
| WO1996001811A1 (en) | 1994-07-11 | 1996-01-25 | The Johns-Hopkins University | 2-substituted 1,25-dihydroxyvitamin d3 derivatives |
| BR9509739A (pt) | 1994-11-21 | 1997-10-21 | Wisconsin Alumni Res Found | Compostos 18,19-dinor-vitamina d |
| US5661140A (en) * | 1994-11-21 | 1997-08-26 | Wisconsin Alumni Research Foundation | 18-nor-vitamin D compounds |
| US5877168A (en) | 1995-02-10 | 1999-03-02 | Chugai Seiyaku Kabushiki Kaisha | Vitamin D derivative with substituent at the 2β-position |
| IL118156A (en) | 1995-05-09 | 2001-08-26 | Duphar Int Res | Vitamin d compounds, their preparation and pharmaceutical compositions containing them |
| US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| US5843928A (en) | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US5945410A (en) | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US6114317A (en) * | 1998-05-21 | 2000-09-05 | Wisconsin Alumni Research Foundation | Method of locking 1α-OH of vitamin D compounds in axial orientation |
| US5972917A (en) * | 1998-05-29 | 1999-10-26 | Bone Care Int Inc | 1 α-hydroxy-25-ene-vitamin D, analogs and uses thereof |
| TW396427B (en) * | 1998-12-16 | 2000-07-01 | United Microelectronics Corp | Method for fabricating double gates in semiconductor |
| WO2001092221A1 (en) * | 2000-05-31 | 2001-12-06 | Wisconsin Alumni Research Foundation | 2-ethyl and 2-ethylidene-19-nor-vitamin d compounds |
| CA2416194C (en) * | 2000-07-14 | 2009-10-06 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength |
| ATE273709T1 (de) * | 2000-09-08 | 2004-09-15 | Wisconsin Alumni Res Found | 1alpha-hydroxy-2-methylene-19-nor- homopregnacalciferol und seine therapeutische verwendungen |
| BR0307896A (pt) * | 2002-03-29 | 2004-12-07 | Wisconsin Alumni Res Found | Método de produção de 1(alfa)-hidroxi-2-metileno-19-nor-homopregnacalcif erol |
| EP1559708A4 (en) * | 2002-10-10 | 2006-07-19 | Wisconsin Alumni Res Found | 2,2-DISUBSTITUTED 1A, 25-DIHYDROXY-19-NORVITAMINE D DERIVATIVE |
| JP5005340B2 (ja) * | 2003-04-10 | 2012-08-22 | ウィスコンシン・アルムニ・リサーチ・ファウンデーション | ２−プロピリデン−１９−ノル−ビタミンｄ化合物 |
| US6894037B2 (en) * | 2003-07-03 | 2005-05-17 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses |
| AU2004266706B2 (en) * | 2003-08-20 | 2009-07-30 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-vitamin D2 compounds |
| US7214670B2 (en) * | 2003-09-24 | 2007-05-08 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 to increase the life expectancy of human beings |
| MXPA06005887A (es) * | 2003-11-25 | 2006-06-27 | Wisconsin Alumni Res Found | Analogos de vitamina d para la prevencion y el tratamiento de la obesidad. |
| US7053075B2 (en) * | 2003-11-25 | 2006-05-30 | Deluca Hector F | Methods for reducing body fat using vitamin D compounds |
| EP1817278B1 (en) * | 2004-11-22 | 2010-06-30 | Wisconsin Alumni Research Foundation | 2-methylene-18,19-dinor-1alfa-hydroxy-homopregnacalciferol and its uses |
| DE602005021245D1 (de) * | 2004-11-22 | 2010-06-24 | Wisconsin Alumni Res Found | 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen |
| DK1848442T3 (da) * | 2005-02-11 | 2012-05-29 | Wisconsin Alumni Res Found | 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2 |
| US7241909B2 (en) * | 2005-05-03 | 2007-07-10 | Wisconsin Alumni Research Foundation | 19,26,27-trinor-1α,25-dihydroxyvitamin D3 compounds |
-
2004
- 2004-04-09 US US10/821,828 patent/US7713951B2/en not_active Expired - Fee Related
-
2005
- 2005-02-04 NZ NZ550234A patent/NZ550234A/en not_active IP Right Cessation
- 2005-02-04 CA CA2562535A patent/CA2562535C/en not_active Expired - Fee Related
- 2005-02-04 EP EP05722702A patent/EP1735277B1/en not_active Expired - Lifetime
- 2005-02-04 AU AU2005235957A patent/AU2005235957B2/en not_active Ceased
- 2005-02-04 AT AT05722702T patent/ATE534623T1/de active
- 2005-02-04 WO PCT/US2005/003378 patent/WO2005102995A1/en not_active Ceased
- 2005-02-04 MX MXPA06011499A patent/MXPA06011499A/es active IP Right Grant
- 2005-02-04 JP JP2007507308A patent/JP4988551B2/ja not_active Expired - Fee Related
-
2010
- 2010-02-19 US US12/709,181 patent/US20100179344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2562535A1 (en) | 2005-11-03 |
| EP1735277A1 (en) | 2006-12-27 |
| AU2005235957B2 (en) | 2011-08-04 |
| WO2005102995A1 (en) | 2005-11-03 |
| CA2562535C (en) | 2012-07-10 |
| US7713951B2 (en) | 2010-05-11 |
| US20100179344A1 (en) | 2010-07-15 |
| EP1735277B1 (en) | 2011-11-23 |
| MXPA06011499A (es) | 2007-01-16 |
| JP2007532540A (ja) | 2007-11-15 |
| US20050227950A1 (en) | 2005-10-13 |
| AU2005235957A1 (en) | 2005-11-03 |
| JP4988551B2 (ja) | 2012-08-01 |
| NZ550234A (en) | 2010-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA03000405A (es) | Uso de 2 alfa-metil-19-nor-20(s)-1alfa,25-dihdroxivitamina d3 para incrementar la resistencia de los huesos. | |
| MXPA03000406A (es) | Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos. | |
| ATE556999T1 (de) | 2-propyliden-19-nor-vitamin d verbindungen | |
| ATE415164T1 (de) | (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung | |
| ATE537834T1 (de) | 2-methylen-19-nor-vitamin d2-verbindungen | |
| Kunz et al. | Effects of immobilization and remobilization on the ankle joint in Wistar rats | |
| De La Mata | Platelet rich plasma. A new treatment tool for the rheumatologist? | |
| NZ337262A (en) | 2-alkyl-19-nor-vitamin D compounds and pharmaceutical compositions thereof | |
| PE20050255A1 (es) | Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos | |
| ATE534623T1 (de) | 2-alkyliden-18,19-dinor-vitamin-d-verbindungen | |
| MX2007006263A (es) | Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos. | |
| MX2007006261A (es) | Analogos de 17,20(z)-deshidro vitamina d y sus usos. | |
| ATE350043T1 (de) | 2-methylen-19-nor-20(s)-25-methyl-1alpha- hydroxycalciferol und seine verwendungen | |
| WO2010006162A3 (en) | 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs | |
| Mombello et al. | Pilon Fractures: Update on treatment | |
| Ferreira et al. | Functional outcome of bicondylar tibial plateau fractures treated with the Ilizarov circular external fixator | |
| Liu et al. | Mesenchymal stem cells and their exosomes mitigate osteoarthritis by restoring the balance between proinflammatory Teffs and Tregs | |
| Fatahi et al. | The effect of aerobic exercise combined with bone marrow mesenchymal stem cells on inflammatory biomarkers levels of the brain in a model of osteoarthritic rat | |
| Huang et al. | Bone Marrow Mesenchymal Stem Cells Inhibits Inflammation and Promotes Chondrocyte Activity in Knee Arthritis Rats | |
| Zhang et al. | Bone Marrow Mesenchymal Stem Cells Exert Anti-Inflammatory and Chondrocyte Activity in Rats with Knee Arthritis | |
| Chen et al. | Growth Arrest Specific Gene 6 Affects Osteogenesis of Bone Marrow Mesenchymal Stem Cells in Inflammatory Environment via MAPK/AKT Signaling Pathway | |
| Iyer | The Adult Hip and Its Disorders | |
| DE60236411D1 (de) | Verwendung von g-csf als zusätzliche behandlung in die wiederherstellung von bindegewebe | |
| Xu et al. | Variation of articular cartilages under abnormal stress | |
| Katsarov et al. | Epiphyseal Complex and Growth Arrest |